pipette
ESEspañol

Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity

Y. Gao, E. Anning, L. Wang, Y. CHENG, L. Wu, J. Wang, F. Liu, Z. Xu, X. Hao, J. Liu, L. Yu, Y. Ding, W. Zhang, D. G. Edwards, Y.-H. Wu, H. L. Chan, D. Hoffman, S. Wang, T. D. Lee, L. B. Dominguez, N. Peled, X. Li, X. Chen, C. H. Rivas, N. Zhao, S. J. Calderon, D. A. Pedroza, A. Smith, N. Guan, Z. Liu, J. Rosen, X. Zhang

PreprintReal-world use

In the authors' words

Despite the remarkable success of immune checkpoint blockade (ICB), durable clinical benefit remains limited to a subset of patients, highlighting the need for predictive biomarkers and new therapeutic targets. Here, we investigated the early immune dynamics associated with anti-PD1 responsiveness using longitudinal single-cell transcriptomics, spatial transcriptomics, and neutrophil-specific genetic perturbations in preclinical models of triple-negative breast cancer. We identified a conserved neutrophil interferon-stimulated gene (ISG) program that emerges before overt tumor divergence and predicts resistance to anti-PD1 therapy. Successful treatment was associated with an early reduction of IFN-responsive neutrophils in both blood and tumor tissues, whereas persistent neutrophil IFN signaling correlated with therapeutic resistance. Mechanistically, genetic disruption of either type I or type II interferon signaling in neutrophils enhanced anti-PD1 efficacy and promoted durable anti-tumor immune memory. Spatial analyses further revealed an inverse association between IFN-responsive neutrophils and tertiary lymphoid structure-enriched regions during effective therapy. Together, these findings identify IFN-responsive neutrophils as early determinants of immunotherapy outcome and establish dynamic neutrophil interferon programs as candidate blood-based biomarkers and therapeutic targets for cancer immunotherapy.

Main resultThe abstract does not state a limitation.

Appeared: Friday, October 2. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.09.30.755684